Stefan D. Anker is Professor of (Tissue) Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin (since June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial College London. He was Professor of Cardiology & Cachexia
Research (W2) at Charité (2002–14), and Professor of Innovative Clinical Trials (W3) in Göttingen (2014–17).
Dr. Anker has authored more than 950 original papers, reviews, and editorials that are well cited (total citations: >87,000, h-index: 128; source: Scopus, 7. September, 2020). He has won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP.
Dr. Anker was Vice President of the European Society of Cardiology (ESC, 2016–18), serving on the board 2012–2018. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC (since 2006); he is past HFA President (2012–14). He is founding Editor-in-Chief of the journal ESC Heart Failure. Dr. Anker also worked in several ESC Guideline task forces (e.g. ESC HF GL 2012 & 2016). Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (since 2008; SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal
of Cachexia, Sarcopenia and Muscle (since 2010).
Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, EMPEROR-HFpEF, RESHAPE-HF2, RELIEVE-HF, REVIVE-HF, DIAMOND-HF, Fair-HFpEF) as well as in the past (incl. FAIR-HF, TIM-HF, ACT-ONE, AUGMENT-HF, BACH & EMPERIALHFpEF).
He served in and chaired several data monitoring committees (DMC’s) and end-point committees.
